Inmune Bio (INMB) EBIT Margin (2021 - 2025)
Inmune Bio (INMB) posted EBIT Margin of 19810.0% for Q1 2025, up 74.83% sequentially from 78692.86% in Q1 2024, and up 5888286.0% YoY from N/an in Q1 2024.
Inmune Bio (INMB) EBIT Margin (2021 - 2025) Analysis & Trends
Inmune Bio has reported EBIT Margin for 5 years, with the latest figure at 19810.0% in Q1 2025.
- Quarterly EBIT Margin rose 5888286.0% year-over-year to 19810.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 94766.0% (up 20976971.0% YoY) and the FY2025 annual result came in at 94766.0%, up 20976971.0% from the prior year.
- EBIT Margin improved to 19810.0% in Q1 2025 per INMB's latest filing, from 78692.86% in the prior quarter.
- Over five years, EBIT Margin peaked at 3974.23% in Q1 2022 and troughed at 113700.0% in Q1 2021.
- A 5-year average of 32314.32% and a median of 19810.0% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin jumped 10972577 bps in 2022, then tumbled 6179023 bps in 2024.
- Over 5 years, EBIT Margin stood at 5539.88% in 2021, then declined by 5 bps to 5816.49% in 2022, then sank by 414 bps to 29925.0% in 2023, then plunged by 163 bps to 78692.86% in 2024, then jumped by 75 bps to 19810.0% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 19810.0%, 78692.86%, and 29925.0% for Q1 2025, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -19,810.00% |
| Mar 31, 2024 | -78,692.86% |
| Dec 31, 2023 | -29,925.00% |
| Sep 30, 2023 | -19,832.56% |
| Jun 30, 2023 | -13,936.96% |
| Mar 31, 2023 | -16,902.63% |
| Dec 31, 2022 | -5,816.49% |
| Sep 30, 2022 | -7,594.90% |
| Jun 30, 2022 | -39,925.00% |
| Mar 31, 2022 | -3,974.23% |
| Dec 31, 2021 | -5,539.88% |
| Sep 30, 2021 | -64,435.71% |
| Mar 31, 2021 | -113,700.00% |